HTHSCI 4II3 Lecture Notes - Lecture 5: Neuroblastoma, Chemokine, Ccl5
Document Summary
While chimeric antigen receptors (cars) have been used extensively to redirect the specificity of autologous t cells against hematological malignancies with striking clinical results, studies of. Studies: car modified primary nk cells: Where do we stand now: preclinical phase, only one clinical trial to date is using technology and is actively recruiting participants results will be out by 2020. Overwhelming problem with current state of cancer therapies that use car technology is their inability to effectively handle solid tumors; at present they are most effective in leukemias. Failures have been attributed to insufficient t cell migration and highly immunosuppressive state of solid tumors. To overcome this car t cells can be used with an oncolytic virus (ov) armed with the chemokine. The ov will have a direct lytic effect on infected malignant cells and facilitate the migration and survival of car t cells. Adenovirus ad524 exerted a potent, dose-dependent, cytotoxic effect on tumor cells, while car.